Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide’s clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders
SAN DIEGO --(BUSINESS WIRE)--Oct. 19, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time ( 5:30 p.m. Eastern time ).
The cerebrospinal fluid (CSF) assay is now validated for melanomas and carcinomas, providing information to help physicians improve treatment decisions for more patients with advanced cancers SAN DIEGO --(BUSINESS WIRE)--Oct. 17, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
Real-world case studies to be presented by leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays,
Presenters include leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees.
SAN DIEGO --(BUSINESS WIRE)--Aug. 22, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC
SAN DIEGO --(BUSINESS WIRE)--Aug. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 .
SAN DIEGO --(BUSINESS WIRE)--Jun. 27, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting firm effective June 24, 2022 .
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’
